Roche has received a major boost from a closely-watched trial looking at a combination of its PD-L1 inhibitor Tecentriq (atezolizumab), the blockbuster Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) which shows that the cocktail shows promise as initial treatment for people with advanced non-squamous non-small cell lung cancer.
The Swiss major has revealed no actual data from the IMpower150 trial but noted that the combo provided a statistically...






